Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could a single X-Ray tame COVID-19 lung inflammation?

NCT ID NCT04466683

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests whether a single, low dose of radiation to the chest can reduce lung inflammation in hospitalized COVID-19 pneumonia patients. Researchers compare two radiation doses (35 cGy and 100 cGy) to standard care. The goal is to see if this treatment lowers the need for ventilators, shortens hospital stays, and reduces deaths.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
low-dose radiation (whole thorax radiotherapy)
What this could lead to
If it works, this could offer a simple, one-time treatment to reduce severe lung inflammation in COVID-19 pneumonia and lower the need for ventilators.
What could go wrong
This is a small, early-phase trial with only 37 participants, so results may not apply broadly. Radiation to the lungs carries unknown risks, and the treatment may not improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

37 people

The number who actually took part.

Started

Aug 2020

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Laboratory-confirmed diagnosis of SARS-CoV-2 pneumonia * Currently hospitalized with COVID-19 * Symptomatic fever, cough and/or dyspnea for \< 9 days * Patient or legal/authorized representative can understand and sign the study informed consent document * Able to be positioned on a linear-accelerator couch for Radiation Therapy delivery * And at least one of the following risk factors for significant pulmonary compromise: 1. Fever \> 102 degrees Fahrenheit during index admission 2. Respiratory rate of ≥ 26 / minute within 24 hours of screening 3. SpO2 ≤ 95% on room air within 24 hours of screening 4. Any patient requiring 4 L/min oxygen therapy to maintain SpO2 \>93% within 24 hours of screening 5. Ratio of partial pressure of arterial oxygen to fraction of inspired air \< 320. * Patients may be enrolled on this trial while concurrently enrolled on other COVID-19 clinical trials. Exclusion Criteria: * Currently requiring mechanical ventilation * Prior thoracic radiotherapy, with the exception of the following: 1. Breast or post-mastectomy chest wall radiation (without regional nodal irradiation) may be included at the discretion of the site primary investigator, and 2. Thoracic skin radiation therapy (without regional nodal irradiation) is allowed. * Known hereditary syndrome with increased sensitivity to radiotherapy, including ataxia-telangiectasia, xeroderma pigmentosum, and Nijmegen Breakage Syndrome * Known prior systemic use of the following drugs: Bleomycin, Carmustine, Methotrexate, Busulfan, Cyclophosphamide, or Amiodarone * History of or current diagnosis of pulmonary fibrosis, or an alternative pulmonary condition responsible for significant lung compromise at the discretion of the site primary investigator * History of lung lobectomy or pneumonectomy * Known history of pulmonary sarcoidosis, Wegener's granulomatosis, systemic lupus erythematosus, rheumatoid arthritis, systemic sclerosis, polymyositis/dermatomyositis, Sjögren's syndrome, mixed connective tissue disease, Churg-Strauss syndrome, Goodpasture's syndrome, or ankylosing spondylitis. * Symptomatic congestive heart failure within the past 6 months including during current hospitalization * History of recent or current malignancy receiving any cytotoxic chemotherapy or immunotherapy within the past 6 months. * History of bone marrow transplantation. * History of any solid organ transplant (renal, cardiac, liver, lung) requiring immunosuppressive therapy. * Females who are pregnant or breast feeding. * Inability to undergo radiotherapy for any other medical or cognitive issues.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID -19 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Boca Raton Regional Hospital Lynn Cancer Institute

    Boca Raton, Florida, 33486, United States

  • Hospital Universitario San Ignacio

    Bogotá, Colombia

  • Indiana University School of Medicine

    Indianapolis, Indiana, 46202, United States

  • Lowell General Hospital Cancer Center

    Lowell, Massachusetts, 01854, United States

  • Loyola University Chicago

    Maywood, Illinois, 60153, United States

  • Miami Cancer Institute

    Miami, Florida, 33176, United States

  • Ohio State University James Cancer Hospital

    Columbus, Ohio, 43210, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.